The 1013–1014 microorganisms present in the human gut (collectively known as the human
gut microbiota) dedicate substantial percentages of their genomes to the degradation and …

Glycosylation is one of the most prevalent posttranslational modifications that profoundly
affects the structure and functions of proteins in a wide variety of biological recognition …

The emerging discipline of bacterial glycoengineering has made it possible to produce
designer glycans and glycoconjugates for use as vaccines and therapeutics. Unfortunately …

Nearly 30% of currently approved recombinant therapeutic proteins are produced in
Escherichia coli. Due to its well-characterized genetics, rapid growth and high-yield …

At first glance, archaea and bacteria look alike; however, the composition of the archaeal
cell envelope is fundamentally different from the bacterial cell envelope. With just one …

Investigations into bacterial protein glycosylation continue to progress rapidly. It is now
established that bacteria possess both N-linked and O-linked glycosylation pathways that …

One of the fastest growing fields in the pharmaceutical industry is the market for therapeutic
glycoproteins. Today, these molecules play a major role in the treatment of various diseases …

Protein folding is a biophysical process by which proteins reach a specific three-dimensional
structure. The amino acid sequence of a polypeptide chain contains all the information …

We performed bottom-up engineering of a synthetic pathway in Escherichia coli for the
production of eukaryotic trimannosyl chitobiose glycans and the transfer of these glycans to …

The beginning of the 20 th century marked the dawn of modern medicine with glycan-based
therapies at the forefront. However, glycans quickly became overshadowed as DNA-and …